Boswood to head Thomson Healthcare

Thomson Healthcare has named Mike Boswood president and CEO, replacing Bob Cullen, who is retiring after 23 years at the company.

Boswood, who is based in London but will move to Ann Arbor, MI, in his new role, was previously president and CEO of Thomson International Legal and Regulatory, where he is credited with delivering solid operating performance, championing numerous growth initiatives and building a strong management team. He also serves as president of the Publisher's Association in the UK. Before joining Thomson in 1997, he served in a number of senior roles at Reed Elsevier, including president, Elsevier Science Inc. in the US, and as managing director of Elsevier Science in the UK. 

Cullen, then president and CEO of Thomson Scientific and Healthcare, took over as the

operational head of the company's healthcare division in 2006, following the resignation of Kevin King.

The company has retooled its healthcare offering in recent years, divesting its journals and med ed business to focus on data and analytics. Thomson sold off its medical publishing business, including the Medical Economics franchise, to Advanstar in 2003, and sold Thomson Medical Education (since rebranded to KnowledgePoint360) to a private equity firm in 2006 while acquiring Solucient. 

You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.